Jean-Pierre J. Issa, MD of Fox Chase Cancer Center Fels Institute for Cancer Research & Molecular Biology at Temple University discusses the treatment trends in 2017 for patients with MDS and AML, which include introduction of new agents, combination therapy, and immunotherapy. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.
Treatment Trends for 2017 in MDS and AML
